menu

IBD & The Evolution of Targeted Therapies – How Far Have We Come?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

IBD: Insights for Better Decisions

IBD & The Evolution of Targeted Therapies – How Far Have We Come?

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program includes updates in the management of inflammatory bowel disease (IBD), with a unique perspective on bringing light to challenges associated with patient management and their journey, and best practices on how to make appropriate interventions in a timely manner. Best practices are predicated on the latest guidelines, with a review of targeted therapies.

  • Target Audience

    This activity has been designed to meet the educational needs of the interdisciplinary team, which includes Gastroenterologists and Primary Care Physicians as well as other healthcare providers involved in managing patients with inflammatory bowel disease (IBD).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Identify the benefits, risks, and clinical utility of current and emerging drug therapies for patients with IBD
    • Discuss the implementation of IBD treatment strategies for gastroenterologists
    • Interpret and apply the latest guidelines for patients with IBD to improve clinical outcomes
  • Accreditation and Credit Designation Statements

    A logo for a credit company Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Disclosure of Relevant Financial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Ugo Iroku, MD, MHS, faculty for this educational activity, receives research grant and manages funds for Takeda; and receives consulting fees for Takeda, Abbvie and Janssen.

    Ayanna Lewis, MD, faculty for this educational activity, has no relevant financial relationships with ineligible companies. 

    Marquis R. Ellison, patient advocate for this educational activity, has no relevant financial relationships with ineligible companies.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    Total CME LLC., planners, and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Commercial Support

    This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

  • Instructions for Completion

    During the period 3/25/2024 through 5/31/2025, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 Jun 2024